2.19
-0.04(-1.79%)
Currency In USD
| Previous Close | 2.23 |
| Open | 2.18 |
| Day High | 2.28 |
| Day Low | 2.12 |
| 52-Week High | 11.69 |
| 52-Week Low | 1.6 |
| Volume | 1.54M |
| Average Volume | 1.12M |
| Market Cap | 162.62M |
| PE | -1.6 |
| EPS | -1.37 |
| Moving Average 50 Days | 3.37 |
| Moving Average 200 Days | 3.12 |
| Change | -0.04 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $152.08 as of November 08, 2025 at a share price of $2.19. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $521.43 as of November 08, 2025 at a share price of $2.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics to Participate in Upcoming November Conferences
GlobeNewswire Inc.
Oct 31, 2025 11:00 AM GMT
SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announ
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
GlobeNewswire Inc.
Oct 24, 2025 11:00 AM GMT
SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today annou
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025
GlobeNewswire Inc.
Oct 20, 2025 8:00 AM GMT
Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follo